Tag
Saurabh Goyal
5 articles
A significant shift in leadership and ownership is underway at Nureca, driven by a Family Settlement Agreement that consolidates control with Saurabh Goyal. Aryan Goyal is stepping down as CEO and director, while transferring his substantial stake to Saurabh Goyal, who will now hold 34.35% of the company. Concurrent off-market share transactions further reinforce this transfer, with Nectar Biopharma reducing its stake to zero and Saurabh Goyal increasing his ownership. These developments signal a potential strategic realignment for Nureca, particularly as the company continues to expand its Dr Trust 360 connected health platform and leverage AI analytics to personalize user experiences.
Nureca Promoter Saurabh Goyal Acquires 32.19 Lakh Shares
Nureca Limited discloses off-market acquisition of 32.19 lakh equity shares by promoter Saurabh Goyal via family settlement agreement.
The transaction, executed on July 2, 2026, increases Goyal's hold
Nureca Limited Promoter Family Settlement Agreement
Nureca Limited discloses a Family Settlement Agreement executed on June 17, 2026 among promoter group members.
Under the agreement, Aryan Goyal and Payal Goyal will transfer their combined 33.74% stak
Nureca Promoter Group Inter-Se Share Transfer
Nureca Limited discloses an inter-se transfer of 60,842 equity shares among promoter group entities via off-market transaction.
Nectar Biopharma transferred shares to Saurabh Goyal, increasing his hol
Nureca Promoter Group Sells 60,842 Shares Off-Market
Nureca Limited discloses an off-market sale of 60,842 equity shares by promoter group entity Nectar Biopharma Private Limited.
The transaction, valued at ₹1.44 crore, reduced Nectar Biopharma's holdin
Nureca Promoter Saurabh Goyal Acquires 60,842 Shares
Nureca Limited discloses an off-market acquisition of 60,842 equity shares by promoter Saurabh Goyal on June 9, 2026.
The transaction increases Mr. Goyal's holding from 33.72% to 34.35% of the company